192 related articles for article (PubMed ID: 29955143)
21. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
24. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
25. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
26. HER2-positive endometrial cancer subtype carries poor prognosis.
Lapińska-Szumczyk S; Supernat A; Majewska H; Gulczyński J; Luczak A; Biernat W; Wydra D; Zaczek AJ
Clin Transl Sci; 2014 Dec; 7(6):482-8. PubMed ID: 25201050
[TBL] [Abstract][Full Text] [Related]
27. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
30. In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D; Roy Chowdhury R; Dutta R; Mukhopadhyay I; Mukhopadhyay A; Roychoudhury S
Gynecol Oncol Rep; 2023 Jun; 47():101209. PubMed ID: 37293351
[TBL] [Abstract][Full Text] [Related]
31. [Endometrial carcinomas in 2021: What to say and what to do?].
Just PA; Genestie C
Ann Pathol; 2022 Mar; 42(2):104-112. PubMed ID: 34340872
[TBL] [Abstract][Full Text] [Related]
32. Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
Baniak N; Fadare O; Köbel M; DeCoteau J; Parkash V; Hecht JL; Hanley KZ; Gwin K; Zheng W; Quick CM; Jarboe EA; Liang SX; Kinloch M
Am J Surg Pathol; 2019 Apr; 43(4):531-537. PubMed ID: 30585826
[TBL] [Abstract][Full Text] [Related]
33. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
34. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
[TBL] [Abstract][Full Text] [Related]
35. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
36. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract][Full Text] [Related]
37. Germline
de Jonge MM; Ritterhouse LL; de Kroon CD; Vreeswijk MPG; Segal JP; Puranik R; Hollema H; Rookus MA; van Asperen CJ; van Leeuwen FE; Smit VTHBM; Howitt BE; Bosse T;
Clin Cancer Res; 2019 Dec; 25(24):7517-7526. PubMed ID: 31492746
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
39. Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.
Bosquet JG; Zhang Q; Cliby WA; Bakkum-Gamez JN; Cen L; Dowdy SC; Sherman ME; Weroha SJ; Clayton AC; Kipp BR; Halling KC; Couch FJ; Podratz KC
PLoS One; 2021; 16(1):e0245664. PubMed ID: 33503056
[TBL] [Abstract][Full Text] [Related]
40. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
